Two Major Phase 3 Trials Confirm Oral Semaglutide Fails to Slow Cognitive Decline in Early Alzheimer’s Patients

Major phase 3 trials published in The Lancet reveal that oral semaglutide does not improve cognitive or functional outcomes for patients with early Alzheimer's.

By: AXL Media

Published: Mar 23, 2026, 6:06 AM EDT

Source: Information for this report was sourced from The Lancet

The Challenge of Repurposing GLP-1 RAs for Neurology

For years, researchers have looked to glucagon-like peptide 1 receptor agonists (GLP-1 RAs)—originally designed for diabetes and obesity—as a potential breakthrough for neurodegenerative disorders. The rationale was built on evidence that these drugs could reduce neuroinflammation and metabolic dysfunction in the brain, two core drivers of Alzheimer's pathology. However, the transition from successful metabolic treatment to disease-modifying Alzheimer's therapy has proven difficult. The latest phase 3 data suggests that the biological benefits seen in cardiovascular and diabetic patients do not automatically translate into the preservation of memory or executive function in a symptomatic Alzheimer’s population.

Rigorous Testing Across Global Clinical Sites

The evoke and evoke+ trials represented a massive international effort, involving 566 sites across 40 different countries. The study population consisted of over 1,800 participants aged 55 to 85, all of whom presented with mild cognitive impairment or mild dementia alongside confirmed amyloid pathology. By utilizing a randomized, double-blind, placebo-controlled design, the researchers sought to determine if a flexible 14 mg oral dose of semaglutide could alter the downward trajectory of the Clinical Dementia Rating Sum of Boxes (CDR-SB) score. This high level of multi-site coordination provided a robust dataset, but the final clinical conclusions remained consistently negative across both independent trials.

Divergence Between Biological Markers and Clinical Reality

One of the most complex findings of the study was the discrepancy between laboratory biomarkers and actual patient outcomes. While the semaglutide group showed measurable reductions in inflammatory markers, such as high-sensitivity C-reactive protein, and modest improvements in cerebrospinal fluid indicators of neurodegeneration, these changes were clinically "silent." In other words, while the drug was technically interacting with the brain's inflammatory pathways as intended, it was not doing so in a way that improved how patients felt, thought, or functioned in their daily lives. This suggests that targeting inflammation alone may be insufficient once Alzheimer’s symptoms have already surfaced.